+44 20 8123 2220
info@marketpublishers.com

Teriparatide– Biosimilar Insight, 2022

https://marketpublishers.com/r/T0A79B203AB1EN.html
Date: January 2022
Pages: 60
Price: US$ 1,500.00 (Single User License)
ID: T0A79B203AB1EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Teriparatide– Biosimilar 2022," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Teriparatide Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Teriparatide Understanding

Teriparatide: Overview

Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Teriparatide is the portion of human parathyroid hormone (PTH), amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulates new bone formation leading to increased bone mineral density.

+44 20 8123 2220
info@marketpublishers.com

Teriparatide Biosimilars: Drugs Chapters

This segment of the Teriparatide report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Teriparatide Biosimilars: Marketed Drugs

Bonsity: Pfenex

Bonsity (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Bonsity is approved in the U.S. under the 505(b) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. Bonsity is indicated for:

Treatment of postmenopausal women with osteoporosis at high risk for fracture

Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture

Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.

Further product details are provided in the report……..

Teriparatide: Therapeutic Assessment

This segment of the report provides insights about the different Teriparatide biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Teriparatide

There are approx. 10+ key companies which are developing the therapies for Teriparatide.

+44 20 8123 2220
info@marketpublishers.com

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Teriparatide pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

+44 20 8123 2220
info@marketpublishers.com

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Teriparatide: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Teriparatide biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Teriparatide biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Teriparatide R&D. The therapies under development are focused on novel approaches to treat/improve Teriparatide.

In June 2020, Pfenex announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States. Teriparatide Injection (also referred to as PF708 and Bonsity) is a prescription medicine approved for several uses, including in postmenopausal women with osteoporosis who are at high risk for having bone fractures.

In August 2019, Gedeon Richter announced that it has launched its biosimilar teriparatide, Terrosa in Europe. The product is approved in adults for the same indications as Eli Lilly's Forsteo, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a

+44 20 8123 2220
info@marketpublishers.com

significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.

Teriparatide Biosimilars Report Insights

Teriparatide Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Teriparatide Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Teriparatide Biosimilars?

+44 20 8123 2220
info@marketpublishers.com

How many Teriparatide biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Teriparatide biosimilars therapeutics?

What are the clinical studies going on for Teriparatide biosimilars and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfenex

CinnaGen

Corium International

Rhein Minapharm Biogenetics

Stada Arzneimittel

Biosidus

Amega Biotech

Azelon Pharmaceuticals

IGI

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Stelis Biopharma

+44 20 8123 2220
info@marketpublishers.com

Asahi Kasei Pharma

Intas Pharmaceuticals

Alkermes

Alkem Laboratories

Paras Biopharmaceuticals

Gedeon Richter

Zydus Cadila

Mochida Pharmaceutical

USV

Key Products

BONSITY

CinnoPar

hPTH(1-34)

Modified PTH

Movymia

Osteofortil

Parathyroid hormone biosimilar

Recombinant parathyroid hormone biosimilar

rhPTH (1-34)

+44 20 8123 2220
info@marketpublishers.com

SBL 001

Teribone

Terifrac

Teriparatide AIR

Terrosa

IFN?-2b

PF708

+44 20 8123 2220
info@marketpublishers.com

Contents

1. KEY INSIGHTS

2. TERIPARATIDE BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America
  4.1.1. US
  4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
  4.3.1. China
  4.3.2. India
  4.3.3. Japan
  4.3.4. South Korea
  4.3.5. Australia
4.4. Rest Of The World
  4.4.1. Brazil
  4.4.2. Mexico
  4.4.3. Argentina
  4.4.4. Saudi Arabia
*More Countries would be added in the final report

5. TERIPARATIDE (REFERENCE PRODUCT: FORTEO)

5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications

+44 20 8123 2220
info@marketpublishers.com

5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

6.1. Clinical Trials Information
6.2. Safety and Efficacy

7. FORTEO BIOSIMILAR: EMERGING OPPORTUNITIES

8. TERIPARATIDE: BIOSIMILARS ASSESSMENT

8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment

9. TERIPARATIDE BIOSIMILARS PROFILES: BY COMPANY

9.1.1. Pfenex
9.1.1.1. BONSITY: Pfenex
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Biosidus
9.1.2.1. Osteofortil: Biosidus
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities

+44 20 8123 2220
info@marketpublishers.com

9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report

10. TERIPARATIDE BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. TERIPARATIDE BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Teriparatide– Biosimilar Insight, 2022
Product link: https://marketpublishers.com/r/T0A79B203AB1EN.html
Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/T0A79B203AB1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970